BioAtla IPO Presentation Deck

Offering Summary Issuer: Ticker/ Exchange: Base offering size: Overallotment option: Use of proceeds: Bookrunners: Co-manager: Expected pricing: Lock-up: Note: Conditionally Active Biologic (CAB) BioAtla, Inc. BCAB/Nasdaq Global Market 9,400,000 shares (-$150.0 million, 100% primary) 1,410,000 shares (100% primary, 15% of base deal) BioAtla intends to use the net proceeds from this offering as follows: • Fund the clinical development of BA3011 in soft tissue and bone sarcoma patients through a Phase 2 clinical trial, and for the treatment of NSCLC patients through Phase 2 bicatla • Fund clinical development of BA3021 for the treatment of NSCLC and for the treatment of melanoma, each through Phase 2 • Fund IND-enabling studies and initial Phase 1 clinical supply of our first two CAB¹ bispecific candidates BTIG • Fund ongoing efforts to develop additional clinical product candidates from BioAtla's CAB platform • Working capital and other general corporate purposes J.P. Morgan, Jefferies, Credit Suisse Tuesday, December 15th, 2020 180 days for the Company, directors, officers and all other pre-IPO shareholders

View entire presentation